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Phenolphthalein, the active ingredient in many laxatives, was
recently found to be a carcinogen in rats and mice (Dunnick and
Hailey 1996; National Toxicology Program, 1996). In the female
mice, one of the affected sites was the ovary, and the ovarian
lesions (stromal cell hyperplasia and stromal cell tumour) were
seen at the lowest dose of phenolphthalein used (3000 ppm in
feed, administered continuously for 2 years). This dose is similar
to the dose in humans consuming two or more phenolphthalein-
containing laxative pills per day. Based on the animal studies, the
United States Food and Drug Association reclassified phenol-
phthalein in over-the-counter medications as ‘not generally recog-
nized as safe’ (Food and Drug Administration, 1999).
Phenolphthalein was voluntarily removed from laxatives sold in
the United States by 1998 and similar actions were taken in Japan,
Canada, and many European countries (e.g., France, Italy,
Germany) (WHO Pharmaceuticals Newsletter, 1998). However,
phenolphthalein is contained in a small number of medications
licensed in the United Kingdom (personal communication,
Medicines Control Agency Information Centre, December 9,
1999) and in other countries (De Smet and Wagenaar, 1998). We
report data from a recent population-based case-control study of
ovarian cancer conducted in the United States that included
detailed information about type and duration of laxative use.
MATERIALS AND METHODS
From 1994 to 1998, 1253 women aged 20–69 with epithelial
ovarian cancer were identified from 39 hospitals in contiguous
counties in eastern Pennsylvania, southern New Jersey and
Delaware (Ness, in press). Cases were excluded who were diag-
nosed more than six months prior to interview (n = 296), critically
ill or dead (n = 69), or untraceable (n = 15), having 873 women
eligible for study. Fourteen physicians did not consent to their
patients’ participation and 92 women refused to participate,
resulting in 767 (88%) completed case interviews of whom 616
had invasive epithelial ovarian cancers and 151 borderline epithe-
lial ovarian tumours. Central pathologic review was conducted on
a random sample of 120 cases resulting in agreement for invasive-
ness in 95% of cases and for cell type in 82% of cases. The original
pathologic diagnosis was then used for all cases.
1637 controls younger than 65 were ascertained by random digit
dialing and were frequency-matched by 5-year age groups and
three-digit telephone exchange to cases. Of these 1215 (74%) were
interviewed and 422 declined. 263 controls aged 65–69 were
ascertained through Health Care Financing Administration
(HCFA) lists and were frequency-matched by age group and zip
(postal) code. 152 of these (58%) were interviewed and 111
declined. Details of the sampling and recruitment process have
been described (Ness, in press). Therefore, of 1900 eligible poten-
tial controls, 1367 (72%) were included. All study subjects gave
informed consent for participation.
Standardized 1.5 hour-long home interviews were conducted. A
life calendar, marked by important events that participants recalled
was used to enhance distant memory. Exposure information was
obtained up to the reference date of six months prior to interview.
A section of the interview on laxative use was added midway
through the study. Approximately half (52.8%, 410 cases and 716
controls) of the participants completed the interview with the laxa-
tive section, and there was little difference in the percent of cases
(53.5%) and controls (52.4%) who provided these data. Two
controls were missing data on telephone area code and so were
excluded from the conditional logistic regression models that
included this matching variable.
Participants were asked if they had ‘ever taken a laxative to help
you move your bowels’ and if they had taken more then six laxa-
tive pills in total up to the reference date. A list of 21 laxatives was
provided to elicit more detailed information. Participants were
asked the name of every laxative they had used, age at first use and
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mate number used each day. The maximum number of different
laxatives used was six. Laxative-specific information was used to
determine if a phenolphthalein-containing laxative had ever been
used. For such laxatives, we calculated total frequency of use
(days), average number of pills per day, cumulative dose and age
at first and last use.
We used the National Toxicology Program report to determine
phenolphthalein-containing brands of laxatives (National
Toxicology Program, 1996), and obtained dose information from
the Physicians’ Desk Reference for Nonprescription Drugs
(Physicians’ Desk Reference, 1990). Phenolphthalein-containing
laxatives ever used were: Agoral, Alophen, Colax, Correctol,
Dialose, Doxidan, Espotabs, Evac-U-Gen, Ex-Lax, Feen-a-Mint,
Kondrumel, LaxCaps, Modane and Phenolax.
We used conditional logistic regression to calculate odds ratios
(OR) and 95% confidence intervals (CI) to examine association
between laxative use and ovarian cancer adjusting for reference
age, race (white, non-white), oral contraceptive use (ever, never),
tubal ligation, nulligravidity, and telephone area code. The
resulting estimates were somewhat weaker than those from
unconditional logistic regression. Only the conditional results are
presented. Additional adjustment for postal zip code for those age
65 and older had little effect on the estimates. Measures of
frequency of use (total days, average number of pills per day, and
cumulative dose), and age at first and last use were also examined.
The referent group was ‘no reported laxative use’ in these models,
and women who had reported using only a non-phenolphthalein-
containing laxative were also included as a separate group.
Additional analyses used the women who had used only non-
phenolphthalein-containing laxatives as the referent group. This is
a much smaller comparison group, but addresses possible
confounding by symptoms or indication for use.
RESULTS
Age was similarly distributed for cases and controls. The median
age was 52.5 years among cases and 51 years among controls.
Overall, 4% of subjects were aged <30, 13% were 30–39, 29%
were 40–49, 30% were 50–59 and 24% were 60–69.
Approximately one-third (31.7%) of the study participants
reported any laxative use (six or more laxative pills ever before
their reference date) and of those, 73.7% had used one or more
phenolphthalein-containing laxative. Use of a phenolphthalein-
containing laxative was weakly associated (OR 1.1) with an
increased risk of ovarian cancer (Table 1). Risk was slightly
increased among women who reported 75 or more days of use (OR
1.2), among women who reported an average of two or more pills
per day (OR 1.2), and among women in the highest quartile of
cumulative dose (adjusted OR 1.2). None of these associations
were statistically significant. When the group who used non-
phenolphthalein containing laxatives is used as the reference
group, these odds ratios are slightly larger: for any use of
phenolphthalein-containing laxatives the OR was 1.4 (95% CI
0.9–2.1), for 75 or more days of use the OR was 1.5 (95%, CI
0.9–2.5), for two or more pills per day the OR was 1.5 (95%, 
CI 0.9–2.4), and for cumulative dose > 10 000 mg the OR was 
1.4 (95%, CI 0.9–2.4) Later age at first use was associated 
with increased ovarian cancer risk, but there was no clear pattern
with age at last use.
DISCUSSION
We observed little association between use of phenolphthalein-
laxatives and ovarian cancer risk, although the data did suggest
risk was increased with increasing exposure (as measured by
number of days used, average number of pills per day, and cumu-
lative dose).
The ovarian lesions seen in the experimental study of phenolph-
thalein in B6C3F1 mice occurred even at the lowest dose used
(3000 ppm in the feed, administered continuously for two years,
equivalent to 311 mg m–2 body surface area) (Dunnick and Hailey
1996). Use of phenolphthalein-containing laxatives at the
prescribed dosage (60–130 mg per pill, 1–2 pills per day) is
comparable to dosage in the mouse study (Dunnick and Hailey
1996; National Toxicology Program, 1996).
Phenolphthalein was shown to induce thymic lymphomas in
heterozygous p53-deficient mice after only 4 months of exposure,
and loss of the p53 wild-type allele was demonstrated in all of the
lymphomas (Dunnick et al, 1997). However, ovarian cancer was
not seen in this study (Dunnick et al, 1997), and there was no
evidence of p53 protein accumulation in the ovarian tumours in the
previous study using B6C3F1 mice (Dunnick and Hailey 1996;
National Toxicology Program, 1996). Phenolphthalein has oestro-
genic properties, and another potential mechanism through which
phenolphthalein could effect ovarian cancer is through its interac-
tion with the estrogen-receptor (Ravdin et al 1987).
A limitation of this study is the retrospectively collected infor-
mation about laxative use. Also, the number of very high dose
exposures, as has been reported in cases of bulimia and other situ-
ations of laxative abuse (Bo-Linn et al, 1983; Bytzer et al, 1989)
was very small (only two women reported use of 10 or more pills
per day), so we had limited power to detect effects in this group.
We did not observe any increased risk of ovarian cancer among
users of laxatives that did not contain phenolphthalein, indicating
that our results were unlikely to have been affected by
confounding by indication for use or symptoms, or by a differen-
tial recall bias (over-reporting of laxative use by cases or under-
reporting by controls). A link between laxative use and ovarian
cancer has not been widely discussed in the media, decreasing the
likelihood that differential recall occurred in this study. The data
collection included detailed information on specific brands and
amount of use. Another strength is that it is a large, population-
based study.
Most western European countries now prohibit sale of phenolph-
thalein-containing laxatives. A limited number of medications
available in the United Kingdom contain phenolphthalein. If
phenolphthalein continues to be used in some countries, additional
epidemiologic studies should be conducted to examine its contribu-
tion to ovarian cancer risk. The studies would need to be very large
to have adequate power to detect the relatively weak associations
observed in our study. This is a commonly used over-the-counter
medication for which alternatives are available, however, so it is a
potentially important modifiable exposure. More than 20% of study
subjects reported using a phenolphthalein-containing laxative. Use
for 180 or more days, or a cumulative dose of ³20 000 mg was
reported by 20% of the women who used phenolphthalein-
containing laxatives and by 5% of all study subjects. The feasibility
and necessity of additional epidemiologic studies would be reduced
if pharmaceutical manufactures voluntarily withdraw phenolph-
thalein-containing laxatives throughout the world.
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Table 1 Phenolphthalein-containing laxative use in relation to ovarian cancer risk
Cases Controls
Adjusted 95%
Category na % na %O R b CIb
Laxative usec
None 282 68.8 487 68.2 1.0 referent
Non-phenolphthalein 27 6.6 66 9.2 0.8 0.5–1.2
Phenolphthalein 101 24.6 161 22.6 1.1 0.9–1.4
Phenolphthalein-laxatives
Total days used
1–9 21 21.0 36 22.5 1.1 0.7–1.7
10–24 21 21.0 42 26.3 1.0 0.6–1.6
25–74 24 24.0 37 23.1 1.1 0.7–1.7
³ 75 34 34.0 45 28.1 1.2 0.8–1.7
(trend P value) (0.36)
Average number pills
per day
< 2 64 67.4 103 66.9 1.1 0.8–1.4
³ 2 31 32.6 51 33.1 1.2 0.8–1.8
Cumulative dose (mg)d
< 1000 19 20.0 43 27.9 0.9 0.6–1.5
1000–2999 23 24.2 36 23.4 1.1 0.7–1.7
3000–10 000 25 26.3 37 24.0 1.1 0.8–1.7
> 10 000 28 29.5 38 24.7 1.2 0.8–1.7
(trend P value) (0.30)
Age first use (years)
≤ 15 26 26.3 48 30.4 0.9 0.6–1.4
16–24 25 25.3 58 36.7 0.9 0.6–1.4
25–34 25 25.3 30 19.0 1.3 0.9–1.9
³ 35 23 23.2 22 13.9 1.5 0.9–2.2
(trend P value) (0.10)
Age last use (years)
≤ 39 31 31.3 60 38.0 1.0 0.7–1.4
40–54 38 38.4 58 36.7 1.2 0.8–1.7
³ 55 30 30.3 40 25.3 1.1 0.8–1.7
(trend P-value) (0.35)
aNumber (cases, controls) with missing data: total days used (1,1); number of pills per day (6,7); cumulative
dose (6,7); age first use (2,3); age last use (2,3). bOR, Odds ratio; CI, Confidence interval. Conditional logistic
regression model, adjusting for age, race, oral contraceptive use, tubal ligation, nulligravidity, and telephone area
code. One control with missing data on tubal ligation excluded. No laxative use is the referent group; use of non-
phenolphthalein containing laxative is also included in the models with frequency (days, pills or dose) of use, age
first use, or age last use of phenolphthalein-containing laxatives. cUse of six or more laxative pills before
reference age. dSummation across all phenolphthalein-containing laxatives of mg phenolphthalein per pill times
average number of pills per day times total number of days used